Minocycline interactions

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (Minocycline label, Warnings and precautions)

Penicillin Because bacteriostatic drugs may interfere with the bactericidal action of penicillin, avoid giving EMROSI in conjunction with penicillin. (Minocycline label, Drug interactions)

Penicillin Because bacteriostatic drugs may interfere with the bactericidal action of penicillin, avoid giving EMROSI in conjunction with penicillin. (Minocycline label, Drug interactions)

Penicillin Because bacteriostatic drugs may interfere with the bactericidal action of penicillin, avoid giving EMROSI in conjunction with penicillin. (Minocycline label, Drug interactions)

Penicillin Because bacteriostatic drugs may interfere with the bactericidal action of penicillin, avoid giving EMROSI in conjunction with penicillin. (Minocycline label, Drug interactions)

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (Minocycline label, Warnings and precautions)

Penicillin Because bacteriostatic drugs may interfere with the bactericidal action of penicillin, avoid giving EMROSI in conjunction with penicillin. (Minocycline label, Drug interactions)

Penicillin Because bacteriostatic drugs may interfere with the bactericidal action of penicillin, avoid giving EMROSI in conjunction with penicillin. (Minocycline label, Drug interactions)

EMROSI is contraindicated in patients with a history of hypersensitivity to any of the tetracyclines [see Warnings and Precautions (5.1) ]. (Minocycline label, Contraindications)

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (Minocycline label, Warnings and precautions)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Minocycline label, Drug interactions)

• Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. (Atovaquone and proguanil label, Drug interactions)

Calcium binds these drugs in the gut and can sharply cut how much is absorbed; separate the doses. (NIH Office of Dietary Supplements, Calcium)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (Cholestyramine label, Drug interactions)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Minocycline label, Drug interactions)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Minocycline label, Drug interactions)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Minocycline label, Drug interactions)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Minocycline label, Drug interactions)

…antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides,… (Glimepiride label, Drug interactions)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Minocycline label, Drug interactions)

Iron binds these drugs in the gut and reduces their absorption; separate the doses. (NIH Office of Dietary Supplements, Iron)

Magnesium-containing supplements and antacids reduce absorption of these drugs; separate the doses by at least two hours. (NIH Office of Dietary Supplements, Magnesium)

Tetracycline and other drugs that interact with magnesium Simultaneous administration of tetracycline with quinapril hydrochloride reduced the absorption of tetracycline by approximately 28% to 37%, possibly due to the high magnesium content in quinapril tablets. (Quinapril label, Drug interactions)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Minocycline label, Drug interactions)

Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. (Sucralfate label, Drug interactions)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Minocycline label, Drug interactions)

Zinc reduces absorption of quinolone and tetracycline antibiotics; take the antibiotic at least two hours before or four to six hours after zinc. (NIH Office of Dietary Supplements, Zinc)

Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations. (Minocycline label, Drug interactions)

Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations. (Minocycline label, Drug interactions)

EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. (Minocycline label, Warnings and precautions)

EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. (Minocycline label, Warnings and precautions)

EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. (Minocycline label, Warnings and precautions)

EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. (Minocycline label, Warnings and precautions)

Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations. (Minocycline label, Drug interactions)

…ranitidine famotidine rifabutin felodipine roxithromycin finasteride Sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin * Refer to PRECAUTIONS , Drug Interactions for information regarding table. (Theophylline label, Drug interactions)